Rucaparib is being tested in a phase 2 trial as adjuvant treatment for TNBC or BRCA-mutated HER2-negative breast cancers with residual disease after preoperative chemotherapy (NCT01074970) [69]; preliminary data presented at ASCO 2014 showed no improvement in 1-year disease-free survival with rucaparib plus cisplatin versus cisplatin alone in the intent-to-treat population; rucaparib did not add substantial toxicity to the cisplatin treatment [70]. The gene discussed is ERBB2; the disease is breast carcinoma.